1. The Effectiveness of Mesenchymal Stem Cell Therapy on COVID-19 Patients at Intensive Care Unit: Case Control Study
- Author
-
Hayri Canbaz, Ufuk Oğuz İdiz, Hayriye Cankar Dal, Fatih Kacıroğlu, Seher Taş, Hikmet Can Çubukçu, Attila Bestemir, Murat Gülşen, İstemi Taha Polat, Abubekir Laloğlu, İbrahim Hakkı Tor, Ekrem Akkurt, Utku Ateş, İsmail Reisli, Esin Koç, Ahmet Cağkan İnkaya, Musa Karakükçü, Mustafa Ceylan, İbrahim C. Haznedaroğlu, and Haluk Akın
- Subjects
covid-19 ,mesenchymal stem cell ,emergency ,mortality ,survival ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC) therapy, which is one of those methods. The aim of our study is to evaluate the effect of MSC treatment applied together with standard treatments on survival. Materials and Methods: This retrospective case-control study evaluates the survival effect of MSC treatment administered to patients treated in intensive care after the development of ARDS due to COVID-19 between March 2020 and March 2021. The age, gender, comorbid disease status, APACHE II score, and overall and comorbidity-based survival rates were compared between patients who received standard medical treatment (SMT) and patients who received MSC treatment together with SMT. Results: There were 62 patients in the group receiving only SMT and 81 patients in the group receiving SMT and MSC. No difference was observed between the groups in terms of age, gender, presence of comorbid diseases, or APACHE II scores. There were also no differences according to Kaplan-Maier analysis for the survival statuses of the groups. There was no serious adverse effect due to MSC treatment among these patients. Conclusion: Our study presents the largest case series in the literature, and it was observed that MSC treatment may not significantly affect overall survival or comorbid disease-based survival, in contrast to many other studies in the literature.
- Published
- 2022
- Full Text
- View/download PDF